Cargando…

Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats

BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Amada, Naoki, Akazawa, Hitomi, Ohgi, Yuta, Maeda, Kenji, Sugino, Haruhiko, Kurahashi, Nobuyuki, Kikuchi, Tetsuro, Futamura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292306/
https://www.ncbi.nlm.nih.gov/pubmed/31487433
http://dx.doi.org/10.1002/npr2.12076
_version_ 1783546084664016896
author Amada, Naoki
Akazawa, Hitomi
Ohgi, Yuta
Maeda, Kenji
Sugino, Haruhiko
Kurahashi, Nobuyuki
Kikuchi, Tetsuro
Futamura, Takashi
author_facet Amada, Naoki
Akazawa, Hitomi
Ohgi, Yuta
Maeda, Kenji
Sugino, Haruhiko
Kurahashi, Nobuyuki
Kikuchi, Tetsuro
Futamura, Takashi
author_sort Amada, Naoki
collection PubMed
description BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic treatment in rats. We also evaluated whether brexpiprazole could suppress enhanced response to D(2) receptors in rats subchronically dosed with another atypical antipsychotic. METHODS: The maximum D(2) receptor density (B (max)) and apomorphine (a D(2) receptor agonist)‐induced stereotypy were measured in rats orally dosed with vehicle, haloperidol (1 mg/kg), or brexpiprazole (4 or 30 mg/kg for B (max), 6 or 30 mg/kg for stereotypy) for 21 days. Then, effects of oral administrations of brexpiprazole (3 mg/kg), aripiprazole (10 mg/kg), and olanzapine (3 mg/kg) against increases in apomorphine‐induced hyperlocomotion and (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrochloride (DOI: a 5‐HT(2A) receptor agonist)‐induced head twitches were evaluated in rats subcutaneously treated with risperidone (1.5 mg/kg/d) via minipumps for 21 days. RESULTS: Haloperidol and brexpiprazole (30 mg/kg: approximately tenfold ED(50) of anti‐apomorphine‐induced stereotypy) but not brexpiprazole (4 or 6 mg/kg) significantly increased the B (max) and apomorphine‐induced stereotypy. Brexpiprazole (3 mg/kg) and olanzapine (3 mg/kg) significantly suppressed both increases in apomorphine‐induced hyperlocomotion and also DOI‐induced head twitches in rats subchronically treated with risperidone, but aripiprazole (10 mg/kg) significantly suppressed only apomorphine‐induced hyperlocomotion. CONCLUSION: Brexpiprazole has a low risk of D(2) receptor sensitization after a repeated administration and suppresses the rebound phenomena related to D(2) and 5‐HT(2A) receptors after a repeated administration of risperidone.
format Online
Article
Text
id pubmed-7292306
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72923062020-12-08 Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats Amada, Naoki Akazawa, Hitomi Ohgi, Yuta Maeda, Kenji Sugino, Haruhiko Kurahashi, Nobuyuki Kikuchi, Tetsuro Futamura, Takashi Neuropsychopharmacol Rep Original Articles BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic treatment in rats. We also evaluated whether brexpiprazole could suppress enhanced response to D(2) receptors in rats subchronically dosed with another atypical antipsychotic. METHODS: The maximum D(2) receptor density (B (max)) and apomorphine (a D(2) receptor agonist)‐induced stereotypy were measured in rats orally dosed with vehicle, haloperidol (1 mg/kg), or brexpiprazole (4 or 30 mg/kg for B (max), 6 or 30 mg/kg for stereotypy) for 21 days. Then, effects of oral administrations of brexpiprazole (3 mg/kg), aripiprazole (10 mg/kg), and olanzapine (3 mg/kg) against increases in apomorphine‐induced hyperlocomotion and (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrochloride (DOI: a 5‐HT(2A) receptor agonist)‐induced head twitches were evaluated in rats subcutaneously treated with risperidone (1.5 mg/kg/d) via minipumps for 21 days. RESULTS: Haloperidol and brexpiprazole (30 mg/kg: approximately tenfold ED(50) of anti‐apomorphine‐induced stereotypy) but not brexpiprazole (4 or 6 mg/kg) significantly increased the B (max) and apomorphine‐induced stereotypy. Brexpiprazole (3 mg/kg) and olanzapine (3 mg/kg) significantly suppressed both increases in apomorphine‐induced hyperlocomotion and also DOI‐induced head twitches in rats subchronically treated with risperidone, but aripiprazole (10 mg/kg) significantly suppressed only apomorphine‐induced hyperlocomotion. CONCLUSION: Brexpiprazole has a low risk of D(2) receptor sensitization after a repeated administration and suppresses the rebound phenomena related to D(2) and 5‐HT(2A) receptors after a repeated administration of risperidone. John Wiley and Sons Inc. 2019-09-05 /pmc/articles/PMC7292306/ /pubmed/31487433 http://dx.doi.org/10.1002/npr2.12076 Text en © 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of NeuropsychoPharmacology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Amada, Naoki
Akazawa, Hitomi
Ohgi, Yuta
Maeda, Kenji
Sugino, Haruhiko
Kurahashi, Nobuyuki
Kikuchi, Tetsuro
Futamura, Takashi
Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
title Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
title_full Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
title_fullStr Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
title_full_unstemmed Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
title_short Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
title_sort brexpiprazole has a low risk of dopamine d(2) receptor sensitization and inhibits rebound phenomena related to d(2) and serotonin 5‐ht(2a) receptors in rats
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292306/
https://www.ncbi.nlm.nih.gov/pubmed/31487433
http://dx.doi.org/10.1002/npr2.12076
work_keys_str_mv AT amadanaoki brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT akazawahitomi brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT ohgiyuta brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT maedakenji brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT suginoharuhiko brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT kurahashinobuyuki brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT kikuchitetsuro brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats
AT futamuratakashi brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats